Citadel Advisors’s Anthera Pharmaceuticals, Inc. ANTH Stock Holding History

Citadel Advisors’s Portfolio ANTH Stock Details ANTH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-43,700	Closed	-$14K	–	9614
2018 Q1	$14K	Buy	+43,700	New	+$65.2K	﹤0.01%	8162
2017 Q2	–	Sell	-1,875	Closed	-$6K	–	8446
2017 Q1	$6K	Sell	1,875 -1,063	-36%	-$5.03K	﹤0.01%	7353
2016 Q4	$15K	Buy	+2,938	New	+$50.9K	﹤0.01%	7131
2016 Q1	–	Sell	-313	Closed	-$12K	–	8702
2015 Q4	$12K	Sell	313 -1,300	-81%	-$57.4K	﹤0.01%	8221
2015 Q3	$79K	Buy	1,613 +300	+23%	+$21K	﹤0.01%	7188
2015 Q2	$91K	Sell	1,313 -25	-2%	-$1.16K	﹤0.01%	7174
2015 Q1	$48K	Buy	1,338 +388	+41%	+$11.5K	﹤0.01%	7414
2014 Q4	$12K	Sell	950 -13	-1%	-$189	﹤0.01%	8086
2014 Q3	$15K	Buy	963 +550	+133%	+$11.6K	﹤0.01%	7631
2014 Q2	$11K	Buy	+413	New	+$10.2K	﹤0.01%	7557

Other funds holding ANTH

Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return

California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

MAM

Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

Citadel Advisors's ANTH Position: Q2 2018 in Review

Citadel Advisors sold out of Anthera Pharmaceuticals, Inc. (ANTH) in Q2 2018, closing a stake of 35,297 shares — an estimated $11K sold.

Citadel Advisors first reported a position in ANTH in Q2 2014 and held it in 12 quarters. The position peaked at $1.09M in Q3 2015. 5 funds tracked by Wall St. Rank hold ANTH as of Q2 2018.

Citadel Advisors reported no remaining Anthera Pharmaceuticals, Inc. position as of Q2 2018 after selling out during the quarter.
Citadel Advisors sold 35,297 Anthera Pharmaceuticals, Inc. shares in Q2 2018, an estimated $11K.
Citadel Advisors first reported a position in Anthera Pharmaceuticals, Inc. in Q2 2014 and held it in 12 quarters.
Citadel Advisors's Anthera Pharmaceuticals, Inc. position peaked at $1.09M in Q3 2015.
5 funds tracked by Wall St. Rank held Anthera Pharmaceuticals, Inc. as of Q2 2018.

Based on Citadel Advisors's 13F filing for Q2 2018, filed 10 Aug 2018.